Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABT 724

Next Previous
Search
Drug Profile

ABT 724

Alternative Names: ABT-724

Latest Information Update: 23 Jan 2013

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Class Benzimidazoles; Erectile dysfunction therapies; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Dopamine D4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Dec 2007 Discontinued - Phase-II for Erectile dysfunction in USA (unspecified route)
  • 09 Jul 2004 Data presented at the XXIVth Congress Collegium Internationale Neuro-Psychopharmacologicum (CINP-2004) have been added to the adverse events and Mens Health pharmacodynamics sections

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top